The TSH (thyroid-stimulating hormone) test is not standardized, and the same blood sample can return results that differ by 20 to 40 percent, depending on which laboratory equipment manufacturer processes the sample[1]. Clinically significant differences were consistently found when comparing the same samples tested on different laboratory machines[1]. The problem is not scientific, but in insufficient enforcement - the Food and Drug Administration has never forced manufacturers to recalibrate to a harmonized standard[1]. These differences have serious implications: patients with high results on one platform may be unnecessarily treated with thyroid hormones, increasing the risk of atrial fibrillation and bone loss, while patients with normal results on another platform may remain untreated and suffer from reduced cholesterol, cognitive symptoms, and increased cardiovascular risk[1]. For example, a TSH of 3.5 mIU/L on one platform may appear as 4.9 mIU/L on another, moving treatment decisions into contentious territory[1]. Fragmented oversight—including a lack of CDC enforcement and FDA approval based on "substantial equivalence"—is preventing needed change[1].